Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

1.6K
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
1.6K
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

1.1K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.1K
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

1.1K
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
1.1K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.8K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-specific gene expression signatures of calcific aortic valve stenosis in a large collection of human tissues.

Atherosclerosis·2026
Same author

Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.

Circulation·2026
Same author

Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease.

The Journal of clinical endocrinology and metabolism·2026
Same author

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction.

Nature genetics·2025
Same author

A Transcriptomic Approach to Sex Differences in Calcific Aortic Valve Stenosis in Patients with a Tricuspid Aortic Valve.

CJC open·2025
Same author

Early-onset multivalvular disease caused by a missense variant in lamin A/C.

HGG advances·2025

Related Experiment Video

Updated: Apr 26, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.0K

Basic mechanisms of calcific aortic valve disease.

Patrick Mathieu1, Marie-Chloé Boulanger1

  • 1Laboratoire d'Études Moléculaires des Valvulopathies (LEMV), Groupe de Recherche en Valvulopathies (GRV), Québec Heart and Lung Institute/Research Center, Department of Surgery, Laval University, Québec, Québec, Canada.

The Canadian Journal of Cardiology
|August 3, 2014
PubMed
Summary

Calcific aortic valve disease (CAVD) lacks medical treatments. Understanding CAVD

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

3.8K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.0K
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

3.8K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.8K

Area of Science:

  • Cardiovascular Biology
  • Pathology
  • Molecular Medicine

Background:

  • Calcific aortic valve disease (CAVD) is the most prevalent heart valve disorder.
  • Currently, no medical interventions exist to prevent or reverse CAVD progression.
  • A deeper understanding of CAVD's underlying mechanisms is crucial for therapeutic development.

Purpose of the Study:

  • To review the molecular mechanisms driving fibrosis and mineralization in CAVD.
  • To explore the roles of lipid retention, inflammation, phosphate signaling, and osteogenic transition in CAVD pathogenesis.
  • To discuss the interplay between these processes and their clinical relevance.

Main Methods:

  • Literature review focusing on molecular and cellular processes in CAVD.
  • Analysis of recent advancements in understanding CAVD pathobiology.
  • Synthesis of information on key regulatory pathways involved in valve disease.

Main Results:

  • Lipid retention, inflammation, phosphate signaling, and osteogenic transition are key molecular drivers of CAVD.
  • Complex interplays exist between these processes, influencing disease progression.
  • Understanding these pathways offers potential targets for novel pharmaceutical therapies.

Conclusions:

  • Elucidating the molecular underpinnings of CAVD, including fibrosis and mineralization, is essential.
  • Targeting lipid retention, inflammation, phosphate signaling, and osteogenic transition may lead to new treatments for CAVD.
  • Further research into these pathways holds promise for developing effective pharmaceutical interventions.